If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply
Objective: Include inhaled levodopa as a therapeutic option in those patients who, due to post-surgical problems, cannot use oral treatments. Background: The development of motor…Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…Using Algorithm Guided Programming to Treat Parkinson’s Disease Patients Implanted with Deep Brain Stimulation
Objective: To compare acute outcomes from Parkinson’s disease patients implanted with Deep Brain Stimulation (DBS) programmed using Algorithm Guided Programming (AGP) versus conventional, standard of…Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Objective: To clarify longitudinal changes in QOL in PD after STN-DBS. Background: While it is well known that motor complications are dramatically improved after subthalamic…Identifying the Most Sensitive Patient-reported Items from the MDS-UPDRS that Predict Initiation of PD Medications in Early Disease
Objective: Objective: To determine the most sensitive combination of MDS-UPDRS Parts IB and II items that accurately predicted the clinically relevant target of dopaminergic therapy…The Impact of VPS35 D620N Mutation on Alternative Autophagy and its Reversal by Estrogen in Parkinson’s Disease
Objective: We investigated the relationship between alternative autophagy and VPS35 D620N mutant-related PD pathogenesis. Background: VPS35 is critically involved in the mechanisms of neurodegeneration observed…Interaction of GCase and ganglioside GM1 in the aggregation of α-Synuclein
Objective: The objective of this work is to investigate the relationship between ganglioside GM1 levels and α-synuclein aggregation in the context of GBA1 mutations. Background:…LRRK2-Associated Parkinsonism With and Without In Vivo Evidence of Pathologic Alpha-Synuclein: Clinical and Biomarker Characterization
Objective: To compare clinical and biomarker features and rate of progression among LRRK2-associated parkinsonism cases with and without in vivo evidence of pathologic alpha-synuclein (asyn)…Cross-Omics Clustering Identifies Common Molecular Patterns in Parkinson’s Disease
Objective: Uncover novel molecular signatures to define Parkinson's disease (PD) patients' clusters using multi-omics integration and evaluate clinical and neuroimaging data. Background: PD is a…Key neural tracts involved in tau depositions and neurodegeneration as revealed by multimodal MRI and PET assays in progressive supranuclear palsy
Objective: Our study aimed to elucidate the impact of tau depositions on brain microstructure and macrostructure in progressive supranuclear palsy (PSP). Background: The link between…
- « Previous Page
- 1
- …
- 140
- 141
- 142
- 143
- 144
- …
- 181
- Next Page »